^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BNT326
i
Other names: BNT326, YL202, BNT 326, YL 202, BNT-326, YL-202
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech, MediLink
Drug class:
Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
Related drugs:
15d
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
P3, N=376, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
16d
A Study of YL202 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P2, N=100, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
BNT326
1m
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P3 trial
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
docetaxel • BNT326
1m
BNT326-01: A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination with other investigational treatments such as BNT327, for people with advanced malignant tumors (2024-517261-16-00)
P1/2, N=172, Recruiting, BioNTech SE
New P1/2 trial
|
pumitamig (BNT327) • BNT326
1m
BNT326-02: A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with advanced non-small cell lung cancer (NSCLC) (2024-519344-32-00)
P1/2, N=88, Not yet recruiting, BioNTech SE
New P1/2 trial
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • pumitamig (BNT327) • BNT326
5ms
BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P1/2, N=420, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
Enrollment open
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
6ms
A Study of YL202 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P2, N=100, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P2 trial
|
BNT326
6ms
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=414, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P1/2 trial
|
Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • BNT326
7ms
BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P1/2, N=420, Not yet recruiting, BioNTech SE
New P1/2 trial
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
8ms
A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients with Advanced Solid Tumors (ChiCTR2500105373)
P2, N=620, Recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • HR positive • KRAS G12C • HER-2 negative • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • EGFR exon 20 insertion • MET exon 14 mutation • BRAF wild-type • EGFR L861Q • RAS mutation • ALK mutation • RET mutation • RAS wild-type • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • EGFR exon 20 mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation • NTRK fusion
|
BNT326
8ms
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)
P1/2, N=550, Not yet recruiting, BioNTech SE
New P1/2 trial
|
itraconazole • pumitamig (BNT327) • BNT326
over1year
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC (clinicaltrials.gov)
P2, N=180, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Active, not recruiting --> Recruiting
Enrollment open • Metastases
|
BNT326
Share via
